ERBB2 and breast carcinoma: We performed a survival analysis on the different subtypes of breast cancer patients from the Kaplan–Meier plotter database [25] and found that the recurrence-free survival time was longer for patients with higher ATP6AP1L expression levels in most subtypes, such as the basal-like, Her2+, and LumA subtypes (Basal: HR = 0.87, 95% CI, 0.64–1.19, log-rank p = 0.39; Her2+: HR = 0.61, 95% CI, 0.44–0.84, log-rank p = 0.0025; LumA: HR = 0.74, 95% CI, 0.5–1.07, log-rank p = 0.11; and LumB: HR = 1.37, 95% CI, 1.01–1.85, log-rank p = 0.044) (Figure 4b–e).